Drugs / Fucoidan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05461508 | Oct 2022 → Jun 2024 | Helicobacter pylori infectious disease, post-bacterial disorder | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07045896 | Jan → Dec 2026 expected | rheumatoid arthritis | Peking University People's Hospital | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06295588 Comparator | Jul 2025 → Dec 2026 expected | — | University of Rochester | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fucoidan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07045896 ↗ |
| Action | Inhibit | “As an SR-A inhibitor, fucoidan markedly suppresses the progression of CIA in mice.” NCT07045896 ↗ |
| Route | Oral | “2000 mg of fucoidan was administered orally twice a day for 12 weeks.” NCT07045896 ↗ |